Cargando…
Chemotherapy Response Score in Ovarian Cancer Patients: An Overview of Its Clinical Utility
The chemotherapy response score has been developed over the last few years as a predictive index of survival outcomes for patients with advanced-stage epithelial ovarian cancer undergoing interval debulking surgery. While its importance in predicting patients at risk of developing recurrences earlie...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054535/ https://www.ncbi.nlm.nih.gov/pubmed/36983157 http://dx.doi.org/10.3390/jcm12062155 |
_version_ | 1785015694478278656 |
---|---|
author | Rodolakis, Ioannis Pergialiotis, Vasilios Liontos, Michalis Haidopoulos, Dimitrios Loutradis, Dimitrios Rodolakis, Alexandros Bamias, Aristotelis Thomakos, Nikolaos |
author_facet | Rodolakis, Ioannis Pergialiotis, Vasilios Liontos, Michalis Haidopoulos, Dimitrios Loutradis, Dimitrios Rodolakis, Alexandros Bamias, Aristotelis Thomakos, Nikolaos |
author_sort | Rodolakis, Ioannis |
collection | PubMed |
description | The chemotherapy response score has been developed over the last few years as a predictive index of survival outcomes for patients with advanced-stage epithelial ovarian cancer undergoing interval debulking surgery. While its importance in predicting patients at risk of developing recurrences earlier seems to be important, its accuracy in determining patients with a shorter overall survival remains arbitrary. Moreover, standardization of the actual scoring system that was initially developed as a 6-tiered score and adopted as a 3-tiered score is still needed, as several studies suggest that a 2-tiered system is preferable. Given its actual importance in detecting patients with shorter progression-free survival, research should also focus on the actual predictive value of determining patients with platinum resistance, as a suboptimal patient response to standard neoadjuvant chemotherapy might help determine patients at risk of an earlier recurrence. In the present review, we summarize current knowledge retrieved from studies addressing outcomes related to the chemotherapy response score in epithelial ovarian cancer patients undergoing neoadjuvant chemotherapy and discuss differences in outcome reporting to help provide directions for further research. |
format | Online Article Text |
id | pubmed-10054535 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100545352023-03-30 Chemotherapy Response Score in Ovarian Cancer Patients: An Overview of Its Clinical Utility Rodolakis, Ioannis Pergialiotis, Vasilios Liontos, Michalis Haidopoulos, Dimitrios Loutradis, Dimitrios Rodolakis, Alexandros Bamias, Aristotelis Thomakos, Nikolaos J Clin Med Communication The chemotherapy response score has been developed over the last few years as a predictive index of survival outcomes for patients with advanced-stage epithelial ovarian cancer undergoing interval debulking surgery. While its importance in predicting patients at risk of developing recurrences earlier seems to be important, its accuracy in determining patients with a shorter overall survival remains arbitrary. Moreover, standardization of the actual scoring system that was initially developed as a 6-tiered score and adopted as a 3-tiered score is still needed, as several studies suggest that a 2-tiered system is preferable. Given its actual importance in detecting patients with shorter progression-free survival, research should also focus on the actual predictive value of determining patients with platinum resistance, as a suboptimal patient response to standard neoadjuvant chemotherapy might help determine patients at risk of an earlier recurrence. In the present review, we summarize current knowledge retrieved from studies addressing outcomes related to the chemotherapy response score in epithelial ovarian cancer patients undergoing neoadjuvant chemotherapy and discuss differences in outcome reporting to help provide directions for further research. MDPI 2023-03-10 /pmc/articles/PMC10054535/ /pubmed/36983157 http://dx.doi.org/10.3390/jcm12062155 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Rodolakis, Ioannis Pergialiotis, Vasilios Liontos, Michalis Haidopoulos, Dimitrios Loutradis, Dimitrios Rodolakis, Alexandros Bamias, Aristotelis Thomakos, Nikolaos Chemotherapy Response Score in Ovarian Cancer Patients: An Overview of Its Clinical Utility |
title | Chemotherapy Response Score in Ovarian Cancer Patients: An Overview of Its Clinical Utility |
title_full | Chemotherapy Response Score in Ovarian Cancer Patients: An Overview of Its Clinical Utility |
title_fullStr | Chemotherapy Response Score in Ovarian Cancer Patients: An Overview of Its Clinical Utility |
title_full_unstemmed | Chemotherapy Response Score in Ovarian Cancer Patients: An Overview of Its Clinical Utility |
title_short | Chemotherapy Response Score in Ovarian Cancer Patients: An Overview of Its Clinical Utility |
title_sort | chemotherapy response score in ovarian cancer patients: an overview of its clinical utility |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054535/ https://www.ncbi.nlm.nih.gov/pubmed/36983157 http://dx.doi.org/10.3390/jcm12062155 |
work_keys_str_mv | AT rodolakisioannis chemotherapyresponsescoreinovariancancerpatientsanoverviewofitsclinicalutility AT pergialiotisvasilios chemotherapyresponsescoreinovariancancerpatientsanoverviewofitsclinicalutility AT liontosmichalis chemotherapyresponsescoreinovariancancerpatientsanoverviewofitsclinicalutility AT haidopoulosdimitrios chemotherapyresponsescoreinovariancancerpatientsanoverviewofitsclinicalutility AT loutradisdimitrios chemotherapyresponsescoreinovariancancerpatientsanoverviewofitsclinicalutility AT rodolakisalexandros chemotherapyresponsescoreinovariancancerpatientsanoverviewofitsclinicalutility AT bamiasaristotelis chemotherapyresponsescoreinovariancancerpatientsanoverviewofitsclinicalutility AT thomakosnikolaos chemotherapyresponsescoreinovariancancerpatientsanoverviewofitsclinicalutility |